Serum osteopontin concentrations in relation to coronary artery disease

Archives of Medical Research

Volumn 46, Issue 2, 2015, Pages 112-117

  Mohamadpour, Amir Hooshang ^a   Abdolrahmani, Leila ^a   Mirzaei, Hamed ^b   Sahebkar, Amirhosein ^a   Moohebati, Mohsen ^b   Ghorbani, Maryam ^c   Ferns, Gordon A ^d   Ghayour Mobarhan, Majid ^e  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c University of Medical Sciences   (Iran)

^d BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

^e MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Atherosclerosis; Coronary artery disease; Osteopontin

Indexed keywords

OSTEOPONTIN; BIOLOGICAL MARKER;

ANGIOCARDIOGRAPHY; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DISEASE ASSOCIATION; DISEASE SEVERITY ASSESSMENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; AGED; BLOOD; BLOOD VESSEL CALCIFICATION; MIDDLE AGED; RADIOGRAPHY; RISK FACTOR;

AGED; BIOMARKERS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPONTIN; RISK FACTORS; VASCULAR CALCIFICATION;

EID: 84928720199     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2015.02.005     Document Type: Article

References (36)

1. st century: updated numbers and updated facts. JCVD 2013, 1:1-2.
2. Abdel-Azeez H.A., Al-Zaky M. Plasma osteopontin as a predictor of coronary artery disease: association with echocardiographic characteristics of atherosclerosis. J Clin Lab Anal 2010, 24:201-206.
3. Safder O., Al-Sharif S., Kari J.A. Pediatric CKD and cardiovascular disease. Cardiovasc Hematol Disord Drug Targets 2014, 14:177-184.
4. Gravallese E.M. Osteopontin: a bridge between bone and the immune system. J Clin Invest 2003, 112:147-149.
5. Sodek J., Ganss B., McKee M. Osteopontin. Crit Rev Oral Biol Med 2000, 11:279-303.
6. Scatena M., Liaw L., Giachelli C.M. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 2007, 27:2302-2309.
7. Takemoto M., Yokote K., Nishimura M., et al. Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis. Arterioscler Thromb Vasc Biol 2000, 20:624-628.
8. Reinholt F.P., Hultenby K., Oldberg A., et al. Osteopontin-a possible anchor of osteoclasts to bone. Proc Natl Acad Sci 1990, 87:4473-4475.
9. Giachelli C.M., Lombardi D., Johnson R.J., et al. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli invivo. Am J Pathol 1998, 152:353-358.
10. Nyström T., Dunér P., Hultgårdh-Nilsson A. A constitutive endogenous osteopontin production is important for macrophage function and differentiation. Exp Cell Res 2007, 313:1149-1160.
11. Murry C.E., Giachelli C.M., Schwartz S.M., et al. Macrophages express osteopontin during repair of myocardial necrosis. Am J Pathol 1994, 145:1450-1462.
12. O'Brien K.D., Kuusisto J., Reichenbach D.D., et al. Osteopontin is expressed in human aortic valvular lesions. Circulation 1995, 92:2163-2168.
13. Fitzpatrick L., Severson A., Edwards W., et al. Diffuse calcification in human coronary arteries. Association of osteopontin with atherosclerosis. J Clin Invest 1994, 94:1597-1604.
14. Tamura A., Shingai M., Aso N., et al. Osteopontin is released from the heart into the coronary circulation in patients with a previous anterior wall myocardial infarction. Circ J 2003, 67:742-744.
15. Bazzichi L., Ghiadoni L., Rossi A., et al. Osteopontin is associated with increased arterial stiffness in rheumatoid arthritis. Mol Med 2009, 15:402-406.
16. Kurata M., Okura T., Watanabe S., et al. Osteopontin and carotid atherosclerosis in patients with essential hypertension. Clin Sci 2006, 111:319-324.
17. Georgiadou P., Iliodromitis E.K., Varounis C., et al. Relationship between plasma osteopontin and oxidative stress in patients with coronary artery disease. Expert Opin Ther Targets 2008, 12:917-920.
18. Marroquin O.C., Kip K.E., Kelley D.E., et al. Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women a report from the Women's Ischemia Syndrome Evaluation. Circulation 2004, 109:714-721.
19. Wolak T. Osteopontin-a multi-modal marker and mediator in atherosclerotic vascular disease. Atherosclerosis 2014, 236:327-337.
20. Denhardt D.T., Noda M., O'Regan A.W., et al. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001, 107:1055-1061.
21. Lai C.F., Seshadri V., Huang K., et al. An osteopontin-NADPH oxidase signaling cascade promotes pro-matrix metalloproteinase 9 activation in aortic mesenchymal cells. Circ Res 2006, 98:1479-1489.
22. Wolak T., Sion-Vardi N., Novack V., et al. N-terminal rather than full-length osteopontin or its C-terminal fragment is associated with carotid-plaque inflammation in hypertensive patients. Am J Hypertens 2013, 26:326-333.
23. Kurata M., Okura T., Kumon Y., et al. Plasma thrombin-cleaved osteopontin elevation after carotid artery stenting in symptomatic ischemic stroke patients. Hypertens Res 2012, 35:207-212.
24. Chen J., Lu Y., Huang D., et al. Relationship of osteopontin and renal function with severity of coronary artery lesions. Int J Clin Exp Med 2014, 7:1122-1127.
25. Yan X., Sano M., Lu L., et al. Plasma concentrations of osteopontin, but not thrombin-cleaved osteopontin, are associated with the presence and severity of nephropathy and coronary artery disease in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2010, 9:70-78.
26. Cho H.J., Cho H.J., Kim H.S. Osteopontin: a multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. Curr Atheroscler Rep 2009, 11:206-213.
27. Mazzali M., Kipari T., Ophascharoensuk V., et al. Osteopontin-a molecule for all seasons. QJM 2002, 95:3-13.
28. Gadeau A.-P., Campan M., Millet D., et al. Osteopontin overexpression is associated with arterial smooth muscle cell proliferation invitro. Arterioscler Thromb Vasc Biol 1993, 13:120-125.
29. Rollo E., Laskin D., Denhardt D. Osteopontin inhibits nitric oxide production and cytotoxicity by activated RAW264.7 macrophages. J Leukoc Biol 1996, 60:397-404.
30. Schmermund A., Erbel R. Unstable coronary plaque and its relation to coronary calcium. Circulation 2001, 104:1682-1687.
31. Ohmori R., Momiyama Y., Taniguchi H., et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 2003, 170:333-337.
32. Ishiyama M., Suzuki E., Katsuda J., et al. Associations of coronary artery calcification and carotid intima-media thickness with plasma concentrations of vascular calcification inhibitors in type 2 diabetic patients. Diabetes Res Clin Pract 2009, 85:189-196.
33. Ärnlöv J., Evans J., Benjamin E., et al. Clinical and echocardiographic correlates of plasma osteopontin in the community: the Framingham Heart Study. Heart 2006, 92:1514-1515.
34. Berezin A., Kremzer A. Circulating osteopontin as a marker of early coronary vascular calcification in type two diabetes mellitus patients with known asymptomatic coronary artery disease. Atherosclerosis 2013, 229:475-481.
35. Kato R., Momiyama Y., Ohmori R., et al. Prognostic significance of plasma osteopontin levels in patients undergoing percutaneous coronary intervention. Circ J 2009, 73:152-157.
36. Nomiyama T., Perez-Tilve D., Ogawa D., et al. Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest 2007, 117:2877-2888.